Proportions and ORs of clearance of total CT-DNA and clearance of viable CT at the vaginal and the rectal site in 560 women who were previously diagnosed with vCT or rCT in FemCure
| Clearance of total CT-DNA | Clearance of viable CT | |||||
| n/N (%) | OR (95% CI) | aOR (95% CI) | n/N (%) | OR 95% CI | aOR (95% CI) | |
| 36/560 (6.4) | 64/560 (11.4) | |||||
| Diagnosis group | ||||||
| (A) vCT and rCT | 1/155 (0.6) | 1*** | 1*** | 6/155 (3.9) | 1*** | 1*** |
| (B) vCT (rCT not tested) | 19/351 (5.4) | 8.81 (1.17 to 66.43) | 8.52 (1.10 to 65.96) | 33/351 (9.4) | 2.58 (1.06 to 6.28) | 2.80 (1.11 to 7.10) |
| (C) vCT (rCT negative) | 8/25 (32.0) | 72.47 (8.54 to 614.95) | 85.45 (9.49 to 769.34) | 13/25 (52.0) | 26.90 (8.67 to 83.46) | 28.98 (8.83 to 95.12) |
| (D) rCT (vCT negative) | 8/29 (27.6) | 58.67 (6.98 to 492.82) | 72.22 (8.18 to 637.54) | 12/29 (41.4) | 17.53 (5.83 to 52.71) | 17.07 (5.49 to 53.10) |
| Years of age | ||||||
| 18–20 | 7/162 (4.3) | 1# | 1 | 7/162 (4.3) | 1** | 1* |
| 21–23 | 10/204 (4.9) | 1.14 (0.43 to 3.07) | 1.11 (0.38 to 3.21) | 26/204 (12.7) | 3.23 (1.37 to 7.66) | 3.36 (1.36 to 8.32) |
| ≥24 | 19/194 (9.8) | 2.40 (0.98 to 5.87) | 1.58 (0.59 to 4.27) | 31/194 (16.0) | 4.21 (1.80 to 9.84) | 3.20 (1.29 to 7.95) |
| Days since initial CT diagnosis | ||||||
| 1–7 | 12/207 (5.8) | 1 | 1 | 23/207 (11.1) | 1 | 1 |
| 8–11 | 16/205 (7.8) | 1.38 (0.63 to 2.99) | 1.58 (0.68 to 3.69) | 24/205 (11.7) | 1.06 (0.58 to 1.95) | 1.02 (0.52 to 1.99) |
| ≥12 | 8/148 (5.4) | 0.93 (0.37 to 2.33) | 0.93 (0.32 to 2.69) | 17/148 (11.5) | 1.04 (0.53 to 2.02) | 0.92 (0.42 to 2.00) |
| Study site (STI clinic) | ||||||
| Limburg | 6/199 (3.0) | 1** | 1** | 17/199 (8.5) | 1 | 1 |
| Rotterdam-Rijnmond | 19/164 (11.6) | 4.22 (1.64 to 10.82) | 6.06 (2.13 to 17.25) | 23/164 (14.0) | 1.75 (0.90 to 3.39) | 2.09 (0.99 to 4.40) |
| Amsterdam | 11/197 (5.6) | 1.90 (0.69 to 5.25) | 2.43 (0.81 to 7.29) | 24/197 (12.2) | 1.49 (0.77 to 2.86) | 1.63 (0.78 to 3.42) |
| Self-reported history of CT | ||||||
| Yes | 15/165 (9.1) | 1.78 (0.89 to 3.55) | 0.95 (0.44 to 2.09) | 28/165 (17.0) | 2.04 (1.20 to 3.47) | 1.33 (0.73 to 2.42) |
| No‡ | 21/395 (5.3) | 1 | 1 | 36/395 (9.1) | 1** | 1 |
| Education | ||||||
| Low | 16/203 (7.9) | 1 | na | 29/203 (14.3) | 1 | na |
| Middle‡ | 11/208 (5.3) | 0.65 (0.30 to 1.44) | 18/208 (8.7) | 0.57 (0.31 to 1.06) | ||
| High | 9/149 (6.0) | 0.75 (0.32 to 1.75) | 17/149 (11.4) | 0.77 (0.41 to 1.47) | ||
| Background | ||||||
| Western | 31/57 (6.0) | 1 | na | 57/517 (11.0) | 1 | na |
| Non-Western | 5/43 (11.6) | 2.06 (0.76 to 5.61) | 7/43 (16.3) | 1.57 (0.67 to 3.69) | ||
| No. of sex partners last 3 months | ||||||
| 0 or 1 | 15/195 (7.7) | 1 | na | 21/195 (10.8) | 1 | na |
| 2 or 3 | 17/269 (6.3) | 0.81 (0.39 to 1.66) | 31/269 (11.5) | 1.08 (0.60 to 1.94) | ||
| ≥4 | 4/96 (4.2) | 0.52 (0.17 to 1.62) | 12/96 (12.5) | 1.18 (0.56 to 2.52) | ||
Clearance of total CT-DNA: at follow no total CT-DNA detected at both anatomic sites; clearance of viable CT: at follow-up no total CT-DNA detected or only non-viable CT detected at both anatomic sites.
This model includes diagnosis group, age, days since initial CT test (diagnosis), and study site (STI clinic); viability polymerase chain reaction is used to test for viable CT; na (variable not entered into the multivariable model to calculate adjusted OR).
*Overall p value 0.01 to <0.05, **overall p value 0.001 to <0.01, ***overall p value <0.001.
†Overall pvalue 0.05 to <0.07.
‡The few cases with unknown information are attributed to this category in analyses.
aOR, odds ratio in the multivariable analyses; CI, Confidence Interval; CT, Chlamydia trachomatis; OR, OR in univariable analyses; rCT, rectal Chlamydia trachomatis; vCT, vaginal Chlamydia trachomatis.